Fraiser Kansteiner is a staff writer at Fierce Pharma. He covers a range of topics including pharmaceutical manufacturing, drug delivery, and the impacts of COVID-19, with a focus on medicine and healthcare, pharmaceuticals, and public health. Fraiser's work has been featured in NewsBreak, Biotech, Fierce Pharma, and RealClearHealth.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Fraiser Kansteiner's coverage primarily revolves around the healthcare and pharmaceutical industry, with a focus on regulatory announcements, press releases, and data citations. To effectively reach out to Fraiser, consider providing insights into pharmaceutical industry trends, drug developments or FDA regulations. Sources with access to unpublished data or exclusive information about pivotal events within the healthcare sector may be of particular interest to him.
Since Fraiser does not specify any geographic focus in his articles, it is likely that he covers global pharmaceutical news and would be interested in international perspectives on key issues within the industry.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Fraiser Kansteiner, Darren Incorvaia
As an outbreak of Ebola in central Africa continues to worsen, the federal government has tapped a little-known biotech in San Diego to provide doses of an experimental antibody that may be used to treat the deadly virus.
By: Fraiser Kansteiner
After the drug’s local license holder called for a brief pause in new patient starts last week, doctors in Japan can once again prescribe Amgen’s rare autoimmune disease med Tavneos (avacopan), alb
By: Fraiser Kansteiner
A web of mail-order pharmacies, wholesalers and patient services groups connected to the self-styled largest Pentecostal denomination in the U.S.
By: Fraiser Kansteiner
More than three years after Gilead Sciences’ hepatitis D drug bulevirtide was rebuffed by the FDA on manufacturing and delivery concerns, the treatment has redeemed itself by scoring a green light
By: Fraiser Kansteiner
As regulatory, pricing and policy dynamics whipsaw in the United States, healthcare and life sciences firms are facing enormous pressures to keep
By: Fraiser Kansteiner
Amid a nearly $1 billion GLP-1 manufacturing expansion that began in 2024, CMDO CordenPharma is doubling down on its peptide capacity ambitions.
By: Fraiser Kansteiner
As AbbVie continues to capitalize on its deal for ImmunoGen with the growth of commercial antibody-drug conjugate (ADC) Elahere, another of the acquired company’s clinical assets has crossed the FD
By: Fraiser Kansteiner
Amid shifts in attitudes around family planning and contraception—and as the advent telehealth outfits like Hims & Hers and Ro define a new era of consumer-driven healthcare—the lack of a medic
By: Fraiser Kansteiner
As governments and health authorities rush to meet the moment of a worsening Ebola outbreak in central Africa, Merck & Co.
By: Fraiser Kansteiner
As its ultra-rare disease med Miplyffa strengthens its foothold in the U.S., Zevra Therapeutics’ CEO believes the launch has the potential to convert the American treatment landscape for Niemann-Pi
